Adelphi Group (United Kingdom)

Recent papers from Adelphi Group (United Kingdom)

1. Imipenem/Cilastatin/Relebactam for MDR Pseudomonas aeruginosa: Real-World Clinical Effectiveness and Contexts of UseAntibiotics · 2026
2. Sex differences in the clinical presentation of patients with transthyretin amyloid cardiomyopathy; results from a real-world studyEuropean Heart Journal · 2026
3. Mobilizing core and country-tailored implementation strategies to accelerate Lipoprotein(a) testing across Europe: findings from the Lp(a)CCELERATE contextual analysisEuropean Heart Journal · 2026
4. Impact of peak provoked left ventricular outflow tract gradients on health-related quality of life in patients with hypertrophic cardiomyopathy: a real-world cross-sectional surveyEuropean Heart Journal · 2026
5. Assessment of disease burden among moderate to severe pediatric psoriasis patients and their caregivers: A real-world survey in the United StatesJournal of Dermatology for Physician Assistants · 2026
6. Describing Patient Characteristics, Treatment Patterns, and Disease Burden Among Patients with Alopecia Areata in Mexico: A Secondary Analysis of the Adelphi Real World Alopecia Areata Disease Specific ProgrammeDermatology and Therapy · 2026
7. Real-World First-Line Treatment Characteristics and Physician Drivers in Advanced/Metastatic Non–Small Cell Lung Cancer, PD-L1 ≥ 50%, and without Actionable Genomic AlterationsOncology and Therapy · 2026
8. Real‐world radical cystectomy use in high‐risk non‐muscle‐invasive bladder cancer: a global surveyBJU International · 2026
9. Patient Experience with Treatment of HAE Attacks: Results from a Real-World Survey of Physicians and Their PatientsAdvances in Therapy · 2026
10. Patient Journey, Disease Burden, Treatment Patterns, and the Impact of Delayed Diagnosis Among Patients With Sjögren's Disease: A Real‐World US SurveyACR Open Rheumatology · 2026
11. Consensus recommendations for the management of locally advanced rectal cancerESMO Gastrointestinal Oncology · 2026
12. Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United StatesJournal of Dermatological Treatment · 2026
13. Observational study on initiation of dapagliflozin in heart failure with reduced ejection fraction in the United KingdomFrontiers in Cardiovascular Medicine · 2026
14. Real‐World Experience With Emicizumab for Haemophilia A From the Physician Perspective in a Real‐World Clinical SettingHaemophilia · 2026
15. Inadequate Disease Control with Current Therapies Among Patients with a History of Moderate-to-Severe Atopic DermatitisDermatitis · 2026
16. Agreement between people with obesity and their treating physicians on behavioral and psychological phenotypes in real-world obesity careObesity Pillars · 2026
17. Real-World Steroid Burden, Treatment Patterns, and Rheumatologists’ Perceptions on Advanced Therapy in Giant Cell ArteritisRheumatology and Therapy · 2026
18. Physician and Patient Perception of Disease, Symptomatology, and Treatment Administration Preference in Paroxysmal Nocturnal Haemoglobinuria: Results from a Real-World SurveyAdvances in Therapy · 2026
19. Derivation of score interpretation thresholds in clinical outcome assessments measuring cognitive impairment associated with schizophreniaSchizophrenia Research · 2026
20. Patient perspectives from the BEYOND Delphi panel: burden of remaining symptoms and their fluctuations, despite treatment, in patients with generalised myasthenia gravisBMC Neurology · 2026